Want to see IMNN full AI Analyst Report?
IMNN Stock Chart & Stats
$3.10
-$0.06(-6.43%)
At close: 4:00 PM EST
$3.10
-$0.06(-6.43%)
Day’s Range― - ―
52-Week Range$1.59 - $8.19
Previous CloseN/A
Volume151.93K
Average Volume (3M)54.97K
Market Cap
$7.44M
Enterprise Value$10.90
Total Cash (Recent Filing)$4.79M
Total Debt (Recent Filing)$911.75K
Price to Earnings (P/E)―
Beta-0.69
Next Earnings
Aug 06, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.86
Shares Outstanding4,202,118
10 Day Avg. Volume25,800
30 Day Avg. Volume54,972
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.00Price Target Upside287.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Phase II Overall Survival BenefitA ~14.7-month median overall survival gain is a durable, clinically meaningful endpoint that materially strengthens the program's therapeutic value proposition. Such a large OS signal can de-risk regulatory discussions, attract partners and payers, and improve commercial prospects if replicated in Phase III.
Pivotal Phase III Progressing With IDMC SupportIDMC continuation and active site enrollment provide durable operational validation: independent safety oversight, intact trial design, and investigator engagement reduce execution risk. Momentum at early sites suggests the company can meet enrollment milestones needed to preserve the Phase III value proposition.
Non-dilutive Structured Financing And Cost DisciplineSecuring $10M via planned non-dilutive structures and instituting a reorganization to lower G&A are durable actions that extend runway without immediate heavy equity dilution. This improves the company's ability to fund pivotal enrollment and maintain negotiating leverage with partners over the medium term.
Bears Say
Persistent Negative Cash Flow And Funding DependenceSustained negative operating and free cash flow is a structural constraint for a clinical-stage biotech: it requires repeated external financings, increases dilution risk, and forces trade-offs between development programs. Even with burn improvement, continued dependence on external capital is a long-term vulnerability.
Prolonged Phase III Timeline To Pivotal ReadoutA last-patient date in Q1 2029 means several years before a definitive regulatory filing and commercialization. Extended timelines raise cumulative trial costs, heighten execution and competitive risks, and delay potential revenue, intensifying reliance on bridge financing and strategic partnerships.
Unblinded Open-label Pivotal Design RiskAn open-label pivotal design creates structural assessment and bias risks that can complicate regulatory review and payer/perception outcomes. Even with data access controls, lack of blinding can affect outcome interpretation, comparators, and the perceived robustness of efficacy signals over the long term.
Imunon News
IMNN FAQ
What was Imunon, Inc.’s price range in the past 12 months?
Imunon, Inc. lowest stock price was $1.59 and its highest was $8.19 in the past 12 months.
What is Imunon, Inc.’s market cap?
Imunon, Inc.’s market cap is $7.44M.
When is Imunon, Inc.’s upcoming earnings report date?
Imunon, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 14 days.
How were Imunon, Inc.’s earnings last quarter?
Currently, no data Available
Is Imunon, Inc. overvalued?
According to Wall Street analysts Imunon, Inc.’s price is currently Undervalued.
Does Imunon, Inc. pay dividends?
Imunon, Inc. does not currently pay dividends.
What is Imunon, Inc.’s EPS estimate?
Imunon, Inc.’s EPS estimate is -0.87.
How many shares outstanding does Imunon, Inc. have?
Imunon, Inc. has 4,202,118 shares outstanding.
What happened to Imunon, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Imunon, Inc.?
Currently, no hedge funds are holding shares in IMNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Imunon, Inc.
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
IMNN Stock 12 Month Forecast
Average Price Target
$12.00
▲(287.10% Upside)
Technical Analysis
Ownership Overview
5.33% Insiders
0.94% Mutual Funds
9.11% Other Institutional Investors
83.50% Public Companies and
Individual Investors